RZLT Rezolute Inc

Price (delayed)

$4.485

Market cap

$431.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$421.75M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 6

Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric ...

Highlights
Rezolute's quick ratio has soared by 89% YoY and by 12% from the previous quarter
RZLT's debt is down by 37% year-on-year and by 14% since the previous quarter
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ
Rezolute's net income has decreased by 12% YoY but it has increased by 3.3% from the previous quarter

Key stats

What are the main financial stats of RZLT

RZLT stock price

How has the Rezolute stock price performed over time
Intraday
-2.07%
1 week
37.16%
1 month
35.91%
1 year
5.53%
YTD
90.04%
QTD
47.05%

Financial performance

How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.25M
Net income
-$81.49M
Gross margin
N/A
Net margin
N/A
Rezolute's operating income has decreased by 13% YoY but it has increased by 3% from the previous quarter
Rezolute's net income has decreased by 12% YoY but it has increased by 3.3% from the previous quarter

Price vs fundamentals

How does RZLT's price correlate with its fundamentals

Growth

What is Rezolute's growth rate over time

Valuation

What is Rezolute stock price valuation
P/E
N/A
P/B
3.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has increased by 29% YoY and by 12% QoQ
The stock's price to book (P/B) is 108% more than its 5-year quarterly average of 1.8 and 21% more than its last 4 quarters average of 3.1
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ

Efficiency

How efficient is Rezolute business performance
The company's return on invested capital rose by 16% YoY and by 11% QoQ
The ROE is up by 16% year-on-year and by 9% since the previous quarter
RZLT's return on assets is up by 14% year-on-year and by 8% since the previous quarter

Dividends

What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RZLT.

Financial health

How did Rezolute financials performed over time
Rezolute's quick ratio has soared by 89% YoY and by 12% from the previous quarter
Rezolute's current ratio has soared by 88% YoY and by 12% from the previous quarter
RZLT's debt is 99% smaller than its equity
RZLT's debt to equity has dropped by 50% year-on-year
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.